We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

107 hedge funds and large institutions have $281M invested in Pacific Biosciences in 2017 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 38 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 16

1% more funds holding

Funds holding: 106 → 107 (+1)

0.05% more ownership

Funds ownership: 70.92% → 70.97% (+0.05%)

11% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 38

31% less capital invested

Capital invested by funds: $406M → $281M (-$125M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

99% less call options, than puts

Call options by funds: $5K | Put options by funds: $722K

Holders
107
Holders Change
+1
Holders Change %
+0.94%
% of All Funds
2.67%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
17
Increased
34
Reduced
38
Closed
16
Calls
$5K
Puts
$722K
Net Calls
-$717K
Net Calls Change
+$3.13M

Top Buyers

1
Capital World Investors
Capital World Investors
California
+$26.6M
2
CCM
Consonance Capital Management
New York
+$15.5M
3
OIM
Oracle Investment Management
Connecticut
+$11.1M
4
MC
Maverick Capital
Texas
+$6.17M
5
FCM
Frontier Capital Management
Massachusetts
+$6.07M

Top Sellers

1
Credit Agricole
Credit Agricole
France
-$77.8M
2
GGHC
Gilder Gagnon Howe & Co
New York
-$10M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.61M
4
Morgan Stanley
Morgan Stanley
New York
-$2.71M
5
Allianz Asset Management
Allianz Asset Management
Germany
-$2.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
101
Barclays
United Kingdom
$2K -$15.4K -3,813 -86%
LTFS
102
Ladenburg Thalmann Financial Services
Florida
$2K – – –
GBBWRPM
103
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$1K – – –
GT
104
Glenmede Trust
Pennsylvania
$1K – – –
LWM
105
Lenox Wealth Management
Ohio
$1K +$706 +175 New
Walleye Trading
106
Walleye Trading
New York
$304 +$279K +69,075 +425%
Credit Agricole
107
Credit Agricole
France
– -$77.8M -2,223,033 Closed
Point72 Asset Management
108
Point72 Asset Management
Connecticut
– -$6.61M -1,279,200 Closed
Allianz Asset Management
109
Allianz Asset Management
Germany
– -$2.05M -396,075 Closed
IHM
110
Iguana Healthcare Management
New York
– -$1.11M -215,000 Closed
Acadian Asset Management
111
Acadian Asset Management
Massachusetts
– -$368K -71,084 Closed
TCM
112
Teza Capital Management
Illinois
– -$153K -29,569 Closed
FTI
113
Fiduciary Trust International
Massachusetts
– -$114K -22,017 Closed
BIA
114
Biondo Investment Advisors
Pennsylvania
– -$137K -19,500 Closed
Principal Financial Group
115
Principal Financial Group
Iowa
– -$78K -15,074 Closed
TA
116
Tiedemann Advisors
New York
– -$60K -11,700 Closed
NIT
117
NumerixS Investment Technologies
British Columbia, Canada
– -$36K -7,000 Closed
CSS
118
Cubist Systematic Strategies
Connecticut
– -$8K -1,527 Closed
EDRH
119
Edmond de Rothschild Holding
Switzerland
– -$6K -1,100 Closed
DADC
120
D.A. Davidson & Co
Montana
– -$5K -1,000 Closed
TRCT
121
Tower Research Capital (TRC)
New York
– -$1K -201 Closed
QCG
122
Quadrant Capital Group
Ohio
– +$1.43K +354 New
1 2 3 4
5

PACB Hedge Fund Activity: Q2 2017 in Review

107 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2017, worth a combined $281M — down 31% from $406M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new PACB positions and 16 closed out — a net gain of 1 holder — while 34 added to existing stakes and 38 trimmed.

The largest buyer was Capital World Investors, adding an estimated $26.6M. The largest seller was Credit Agricole, exiting entirely with an estimated $77.8M sold.

  • 107 institutional investors held Pacific Biosciences (PACB) as of Q2 2017, up from 106 in Q1 2017.
  • Funds reported $281M of Pacific Biosciences stock for Q2 2017, down 31% quarter-over-quarter.
  • 17 funds opened new Pacific Biosciences positions in Q2 2017 and 16 closed out, a net change of +1 holder.
  • The largest Pacific Biosciences buyer in Q2 2017 was Capital World Investors, an estimated $26.6M added.
  • The largest Pacific Biosciences seller in Q2 2017 was Credit Agricole, an estimated $77.8M sold.

Based on aggregated 13F filings for Q2 2017.